BioXcel Therapeutics Completes Key Phase 3 Study

BioXcel Therapeutics shares are trading higher after the company announced the completion of the last patient visit in its pivotal Phase 3 SERENITY At-Home trial, with topline data expected soon to support expanding BXCL501's drug label.